Medication overuse headache in Australia: a call for multidisciplinary efforts at prevention and treatment

Stark, Richard J; McGuire, Treasure; van Driel, Mieke L

doi:10.5694/mja16.00492

Topics

Medication overuse headache (MOH)1 is prevalent, under-recognised and potentially treatable or avoidable using a multidisciplinary approach.

1 Neurology Service, Alfred Health, Melbourne, VIC
2 Department of Medicine, Monash University, Melbourne, VIC
3 University of Queensland, Brisbane, QLD
4 Bond University, Gold Coast, QLD

Correspondence: Richard.stark@monash.edu

Acknowledgements:

We thank Esther Anderson of In Vivo Communications for her assistance in medical writing.

Competing interests:

Richard Stark has received lecture and consulting fees from Allergan, MSD, AbbVie and SciGen, and from In Vivo Academy relating to a Pfizer-sponsored project. He has also undertaken clinical trials for Allergan.

1. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd ed. (beta version). Cephalalgia 2013; 33: 629-808.
2. Williams D. Medication overuse headache. Aust Prescr 2005; 28: 143-145.
3. Therapeutic Goods Administration. Proposal for the re-scheduling of codeine products. Canberra: Australian Government, Department of Health, 2015. https://www.tga.gov.au/media-release/proposal-re-scheduling-codeine-products (accessed Apr 2016).
4. Stark R, Hutton E. Chronic migraine and other types of chronic daily headache. Medicine Today 2013; 14: 29-35.

Online responses are no longer available. Please refer to our instructions for authors page for more information.